Treatment regimens involving the monoclonal anti-CD20 antibody rituximab are the standard of care for patients with CD20-positive non-Hodgkin lymphoma (NHL). It has...
Non-Hodgkin’s lymphoma is a heterogeneous group of lymphoproliferative malignancies with differing patterns of behaviour and responses to treatment. Chemotherapy,...
Lymphoma encompasses a heterogeneous group of haematological malignancies that require complex management. Patients with lymphoma experience a wide range of...